MedTrace Logo

MiSaver® Stem Cell Treatment for Heart Attack (Acute Myocardial Infarction)

NCT04050163 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-03-29

No results posted yet for this study

Summary

The objective of the present study is to establish the safety and efficacy of MiSaver® Stem Cell Treatment After a Heart Attack (Acute Myocardial Infarction)

Conditions

Interventions

BIOLOGICAL

MiSaver®

Intravenous administration of MiSaver® Stem Cell via peripheral vein access.

Sponsors & Collaborators

  • Chung Shan Medical University

    collaborator OTHER

  • Honya Medical Inc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-26
Primary Completion
2023-05-04
Completion
2023-05-04

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04050163 on ClinicalTrials.gov